Rocket Pharmaceuticals, Inc. CEO Gaurav Shah filed a Form 4 on November 20, 2026, disclosing the sale of 2,216 shares of common stock on November 18, 2026, to cover tax withholding obligations arising from the vesting of restricted stock units.

Key Highlights

  • Transaction date: 2,216 shares of common stock were disposed of on November 18, 2026, at a price of $2.178 per share.
  • Purpose: According to the filing, the shares were sold to pay tax withholding obligations in connection with the vesting of RSUs.
  • Direct holdings after transaction: Shah directly beneficially owned 1,051,358 shares following the reported transaction, including RSUs that convert to common stock on a one-for-one basis.
  • Indirect holdings: Shah also holds 207,897 shares indirectly through a spouse and 198,341 shares indirectly through the Gaurav D. Shah Irrevocable Trust.
  • Transaction code: The disposal was coded "S" (open-market or private sale) under Instruction 8.
  • Signatory: The form was signed by Martin Wilson as attorney-in-fact for Gaurav Shah on November 20, 2026.

Shah's RSU Tax-Withholding Sale at Rocket Pharmaceuticals

According to the Form 4 filed with the SEC on November 20, 2026, Gaurav Shah, who serves as CEO of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), disposed of 2,216 shares of the company's common stock on November 18, 2026. The filing states that the shares were sold at $2.178 each and that the purpose of the sale was to satisfy tax withholding obligations connected to the vesting of restricted stock units (RSUs).

Following the reported transaction, the filing discloses that Shah directly beneficially owned 1,051,358 shares. The filing notes that these holdings include RSUs that convert to common stock on a one-for-one basis. In addition to his direct position, Shah held 207,897 shares indirectly through his spouse and 198,341 shares indirectly through the Gaurav D. Shah Irrevocable Trust, according to the filing.

The transaction was reported under transaction code "S." No derivative securities transactions were reported in Table II of the filing. The form was executed by Martin Wilson as attorney-in-fact for Gaurav Shah and filed on November 20, 2026.

What Was Disclosed

Rocket Pharmaceuticals CEO Gaurav Shah disclosed a sale of 2,216 common shares at $2.178 on November 18, 2026, to cover RSU vesting tax obligations, leaving him with 1,051,358 direct shares plus additional indirect holdings through a spouse and an irrevocable trust.